Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats

Lukaszewski, L.; Praissman, Melvin

doi:10.1152/ajpregu.1988.254.1.r17

Cited by 19 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continuous administration of other anorexigenic peptides (cholecystokinin, amylin, GLP-1) by osmotic minipump has also been reported to produce either no effect or a transient reduction in daily food intake in rodents (2,4,11,12,25). One possible explanation for these transient responses is that early peptide-induced reductions in daily food intake and adiposity elicit a delayed compensatory response to restore energy balance mediated by a reduction in leptin signaling to the brain (2,17).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

Chelikani

Haver²,

Reeve³

et al. 2006

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

reduces food intake and weight gain in rats when injected into the peritoneal cavity twice daily for 7 days. Numerous laboratories have failed to confirm that daily injections of PYY(3-36) decrease body weight. Continuous subcutaneous administration of PYY(3-36) by osmotic minipump has been reported to reduce daily food intake in rodents but only during the first 3-4 days of administration. Here we show the effects of different daily patterns of intravenous infusion of PYY(3-36) on food intake, body weight, and adiposity in rats tethered via infusion swivels to computercontrolled pumps. Measurement of food bowl weight recorded by computer every 20 s permitted daily assessment of the instantaneous effects of PYY(3-36) administration on food intake and meal patterns. One-hour intravenous infusions of PYY(3-36) at 30 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 every other hour for 10 days produced a sustained reduction in daily food intake of ϳ20% and decreased body weight and adiposity by 7 and 35%, respectively. Thus dosage pattern is critical for producing a sustained effect of PYY(3-36) on food intake and adiposity.gastrointestinal; body weight; body composition THE GASTROINTESTINAL SYSTEM plays an important sensing and signaling role in control of food intake and regulation of energy reserves (5). A growing number of peptide signals of gastric, intestinal, and pancreatic origin have been shown to inhibit short-term food intake when administered acutely to experimental animals and humans. These include cholecystokinin, amylin, glucagon-like peptide-1 (GLP-1), oxyntomodulin, peptide YY(3-36) ], pancreatic polypeptide, gastrinreleasing peptides (GRPs) GRP-27 and GRP-

show abstract

Section: Discussionmentioning

confidence: 99%

“…4). During the subsequent 10-day treatment period, 1-h IV infusions of PYY(3-36) at 30 pmol⅐kg Ϫ1 ⅐min Ϫ1 significantly reduced food intake on successive days by 31,20,24,21,25,17,19,16,15 and 23%, respectively, compared with the vehicle-treated group (Figs. 4 and 5).…”

Section: Effects Of 1-h IV Infusions Of Pyy(3-36) Every Other Hour Onmentioning

confidence: 95%

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

Chelikani

Haver²,

Reeve³

et al. 2006

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

show abstract

“…Several studies have since shown that continuous systemic administration of PYY(3-36) by osmotic minipump can reduce food intake and body weight in rodents but only transiently (3,36,41,42,44). Other known anorexigenic substances (amylin, glucagon-like peptide-1 receptor agonists, cholecystokinin, melanocortin receptor agonists) have also been reported to produce only transient effects on daily food intake and body weight in rodents when administered continuously by osmotic minipump (3,9,18,20,30,31,35,36,38,41,42,44). Reasons for these inconclusive results include development of a compensatory increase in food intake between bolus injections, tolerance to continuous or frequent administration of the substances, and redundancy and plasticity in the energy regulatory system.…”

mentioning

confidence: 99%

“…Continuous osmotic minipump administration of many known anorexigenic substances [PYY , amylin, glucagon-like peptide-1 receptor agonists, cholecystokinin, melanocortin receptor agonists] has been reported to produce transient reductions in daily food intake in rodents (3,9,18,20,30,31,35,36,38,41,42,44). One possible explanation for these transient responses is that early substance-induced reductions in daily food intake and adiposity elicit a delayed compensatory response to restore energy balance mediated by a reduction in leptin signaling to the brain (5,22).…”

mentioning

confidence: 99%

Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats

Chelikani

Haver²,

Reidelberger³

2007

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 293: R39-R46, 2007. First published April 11, 2007; doi:10.1152/ajpregu.00164.2007 ] is a gut-brain peptide that decreases food intake when administered by intravenous infusion to lean and obese humans and rats. However, chronic administration of PYY(3-36) by osmotic minipump to lean and obese rodents produces only a transient reduction in daily food intake and weight gain. It has recently been shown that 1-h intravenous infusions of PYY(3-36) every other hour for 10 days produced a sustained reduction in daily food intake, body weight, and adiposity in lean rats. Here, we determined whether intermittent delivery of PYY(3-36) can produce a similar response in diet-induced obese rats. During a 21-day period, obese rats (body fat Ͼ25%) received twice daily intraperitoneal infusion of vehicle (n ϭ 18) or PYY(3-36) (n ϭ 24) during hours 1-3 and 7-9 of the dark period. Rats had free access to both a 45% fat solid diet and a 29% fat liquid diet; intakes were determined from continuous computer recording of changes in food container weights. To sustain a 15-25% reduction in daily caloric intake, the initial PYY(3-36) dose of 30 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 was reduced to 10 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 on day 10 and then increased to 17 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 on day 13. This dosing strategy produced a sustained reduction in daily caloric intake of 11-32% and prevented body weight gain (8 Ϯ 6 vs. 51 Ϯ 11 g) and fat deposition (4.4 Ϯ 7.6 vs. 41.0 Ϯ 12.8 g). These results indicate that intermittent intraperitoneal infusion of PYY(3-36) can produce a sustained reduction in food intake and adiposity in diet-induced obese rodents consuming palatable high-fat foods.peptide; anorexia; body weight; body fat PEPTIDE YY (PYY), neuropeptide Y, and pancreatic polypeptide comprise a family of structurally related gut-brain peptides with diverse actions mediated by five known receptors (12). Endocrine cells of the distal gut provide a major source of PYY. Food intake releases at least two major forms of PYY into the circulation: PYY(1-36) and PYY(3-36); other predicted or detected isoforms include Ser 13 -phosphorylated PYY(1-36) and PYY(3-36), glycine-extended carboxyl termini of both the phosphorylated and nonphosphorylated forms, and [Pro 34 ]PYY(3-36) (4,17,21,24). Systemic administration of PYY(3-36) potently inhibits food intake in rodents, monkeys, and humans (11,15,19,27,28,33,40), whereas PYY(1-36) appears to be significantly less potent in rats (15) and humans (39). Targeted deletion of the PYY gene produces an obese phenotype in mice (13). Obese humans appear to have a blunted plasma PYY response to food intake (10, 28); however, PYY(3-36) appears to decrease food intake similarly in lean and obese humans (10, 39). These results suggest that PYY(3-36) may act physiologically to reduce food intake and body adiposity and that insufficient produc...

show abstract

“…The first gut hormone shown to inhibit food intake after exogenous infusion in rodents was CCK (cholecystokinin). Peripheral CCK has a brief but fastacting effect, decreasing food intake, and thus is thought to play a role in satiety and meal termination [41].…”

Section: Gastrointestinal Peptidesmentioning

confidence: 99%

Fetal and perinatal programming of appetite

2005

View full text Add to dashboard Cite

There is increasing concern about the rapidly rising incidence of obesity worldwide and its impact both on mortality, morbidity and the cost of healthcare. In the last 15 years, a large volume of research has linked low birth weight to many adult diseases in humans, such as Type II diabetes, cardiovascular disease, hypertension and the metabolic syndrome. Obesity is a causal factor in all these conditions. There are epidemiological studies linking low birth weight to increased adiposity, but the timing of the insult during gestation seems crucial, as reducing maternal nutrition in late gestation and during lactation causes a reduction in later obesity. Recent studies in animal models have provided clues towards mechanisms of altered appetite regulation following alterations in fetal and neonatal growth. The outcome of these and future studies could prove clinically crucial, particularly in the debate over the benefits of breast feeding, which provides a lower plane of nutrition compared with formula feeding.

show abstract

Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats

Cited by 19 publications

References 0 publications

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats

Fetal and perinatal programming of appetite

Contact Info

Product

Resources

About